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OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
raloxifene is effective as an adjunctive schizophrenia medication in reducing schizophrenia 
symptoms in women with diagnosed schizophrenia.  
 
STUDY DESIGN: A review of three peer-reviewed studies published between 2014 and 2016.  
 
DATA SOURCES: Three randomized control trials. Using PubMed and Cochrane 
Collaboration, studies were chosen if they were peer-reviewed, related to the topic question, 
published after 2014, and if they had results containing POEMs.  
 
OUTCOMES MEASURED: Decrease in schizophrenia Symptoms, as measured by the 
Positive and Negative Syndromes Scale (PANSS).  
 
RESULTS:  Two studies found a statistically significant reduction in schizophrenia symptoms 
with the Raloxifene treatment group compared to the control group with p-values of 0.005 and 
0.02 respectively (Usall J, Herta-Ramos E, Labad J, et al. Schizophr Bull. 2015;42(2):309-17. 
doi:10.1093/schbul/sbv149; Kulkarni J, Gavrilidis E, Gwini, S, et al. JAMA Psychiatry. 
2016;73(9):947-954. doi: 10.1001/jamapsychiatry.2016.1383). One study did not find a 
statistically significant reduction in schizophrenia symptoms with a p-value of 0.18. (Kianimehr 
G, Fatehi F, Hashempoor S, et al. Daru. 2014;22(1):55. doi:10.1186/2008-2231-22-55).  
 
CONCLUSIONS: The results from this study do not give a definitive answer to the research 
question. Future studies should consider including a larger study population, limiting participants 
to post-menopausal women with schizophrenia who are on the same antipsychotic medications, 
running studies for longer periods of time, and comparing various doses of treatment to each 
other. 
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 Schizophrenia is a psychological disorder characterized by disordered thinking, 
behaviors, and emotions, which causes impaired functioning. Positive symptoms of 
schizophrenia include delusions, hallucinations, and disordered speech. Negative symptoms 
include social withdrawal, lack of eye contact, and loss of interest in everyday activities. This 
can lead to consequences including anxiety, social isolation, substance abuse, and suicide. 
 Many people in the United States meet the criteria for schizophrenia, with an estimated 
prevalence of 1% of the population.  Schizophrenia is more prevalent in males at a ratio of 1.4:1, 
and women are most likely to be diagnosed with schizophrenia around ages 25-35, and again 
after menopause, which is later compared to men.2 Schizophrenia accounts for between 1.6 and 
2.6% of total health care expenditures, with an economic burden of around $60 billion dollars 
per year in the United States.3 Men are more likely to be hospitalized for schizophrenia, and it is 
estimated that in two years there were 382,000 emergency room visits related to schizophrenia in 
the United States.4 The cause of schizophrenia is unknown; however, it is theorized that there are 
several hormones that are implicated in the disease, including estrogen and dopamine. As women 
often develop schizophrenia at a later age, it is proposed that estrogen may play a role in 
protecting women from developing schizophrenia.  
 There have been many methods of treating schizophrenia. Traditionally, the gold 
standards of treatment for schizophrenia included first generation anti-psychotics, such as 
haloperidol and chlorpromazine, and second generation anti-psychotics, such as aripiprazole, 
risperidone, and clozapine. Other methods of treatment have included psychotherapy, and 
electroconvulsive therapy.5 A new method of treatment that is being considered in treatment of 
schizophrenia in women is raloxifene, which is a Selective Estrogen Receptor Modulator. This 
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medication is already used in with certain diseases like osteoporosis and breast cancer where 
estrogen plays a role in the disease course10. This method is being contemplated due to the theory 
that estrogen may play a protective role against schizophrenia. In addition, it is suggested due to 
the later age of diagnosis in women compared to men, and due to the fact that symptoms of 
schizophrenia usually present themselves in phases of the menstrual cycle which coincides in 
times of lower estrogen levels. The severity of schizophrenia also increases in age with women.5 
OBJECTIVE: 
 The objective of this selective EBM review is to determine whether or not raloxifene is 
effective as an adjunctive schizophrenia medication in reducing schizophrenia symptoms in 
women with diagnosed schizophrenia. 
METHODS: 
 The population selected for this evidence based review included women diagnosed with 
schizophrenia that were refractory to conventional treatment. The intervention of choice was 
raloxifene as adjunctive therapy to antipsychotic medication. This was compared to a group that 
received an adjunctive placebo. The outcome measured was the decrease in positive and negative 
symptoms associated with schizophrenia, as measured on the Positive and Negative Syndrome 
Scale (PANSS). Three double blind randomized control trials were selected for this review. 
Data Sources:  
 The keywords included in searches for this review were schizophrenia and raloxifene. 
Each of the articles were published in peer reviewed journals in English. The author utilized 
Cochrane Collaboration and PubMed to select these articles, and chose them based on them 
pertaining to my research question, and if they studied Patient Oriented Evidence that Matters 
(POEMS).  
                                                                               Wilcox, Raloxifene to treat Schizophrenia 3 
 Table 1. Demographics and Characteristics of Included studies 
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 Inclusion criteria were studies that were double blind RCTs, published later than 2013, 
and that only included women over age 40. Articles excluded were articles pertaining to men or 
women under the age of 40. The reported statistics from these articles were mean change from 
baseline, p-value, NNT, EER, CER, RBI, ABI, and F-score. Table 1 includes the demographics 
and characteristics of the included studies.  
OUTCOMES MEASURED 
 In all three trials, the outcomes measured were positive and negative symptoms of 
schizophrenia, as measured by the PANSS. The positive symptoms included items like 
hallucinations and delusions, and the negative symptoms included items like blunted affect, poor 
rapport, and emotional withdrawal. The PANSS also measured general pathology which includes 
items like anxiety, tension, somatic complaints, and poor attention. These scales were completed 
by participants, and outcomes were measured by the researchers involved.5,6,7 
RESULTS 
 Each of the three studies were double blind RCT’s that included women over the age of 
40 who had a history of diagnosed schizophrenia. These studies were all conducted at 
psychological institutions.5,6,7 Two of the studies by Usall et al., and Kianimehr et al., included 
only post-menopausal women in their research.5,6 One study by Kulkarni et al. also included 
premenopausal women who were older than 40.7 Usall et al., and Kulkarni et al. included 
patients already on adjunctive antipsychotic medications, while the study by Kianimehr et al. 
included patients not currently on an antipsychotic medication prior to the study.5,6,7  
 These studies excluded certain patients which are listed in Table 1 above. In the study by 
Usall et al. thirteen patients were lost to follow up.5 Kulkarni et al. lost ten patients due to 
patients that stopped taking their medication, and one patient who needed to be hospitalized for a 
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reason unrelated to schizophrenia.7 All patients were accounted for in the study be Kianimehr et 
al.6 
 Usall et al. used mean change from baseline, pertaining the score on the PANSS from the 
start of the study compared to week 24, to evaluate the results of adjunctive raloxifene therapy. 
The mean change from baseline in the treatment group was -10.24 compared to the placebo 
group having a mean change from baseline of -0.063. These changes represented a p-value result 
of 0.005, which is less than 0.05, indicating that this study showed a statistically significant 
decrease in schizophrenia symptoms with the addition of adjunctive raloxifene treatment.5 These 
results are reflected in Table 2.  
Table 2. Mean Change from baseline after 24 weeks of treatment5 
Mean Change from 
baseline: control 
group 




-0.063 -10.24 0.005 
 
 Kulkarni et al. measured mean change from baseline, pertaining to the score on the 
PANSS between the start of the study and after twelve weeks of treatment.  The researchers 
found that the mean change from baseline for the control group was -3.82, whereas the mean 
change from baseline for the treatment group was -10.18. These changes represented a p-value 
result of 0.02, which is less than 0.05, indicating that the study showed a statistically significant 
decrease in schizophrenia symptoms with adjunctive raloxifene. Researchers in this study also 
dichotomized the data by calculating the number of patients who had at least a 20% reduction in 
symptoms on the PANSS comparing the raloxifene group to the control group. In the control 
group 13% of the patients had a 20% reduction, compared to 42% in the experimental group.7 
The experimental event rate (EER), control event rate (CER), relative benefit increase (RBI), 
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absolute benefit increase (ABI) and numbers needed to treat (NNT) are shown in Table 3 below. 
The NNT refers to the number of patients needed to be treated with raloxifene for a patient to 
have a decrease in schizophrenia symptom. By definition the NNT is the average number of 
patients that should be treated to prevent a “bad” outcome from occurring.  













P-Value CER EER RBI ABI NNT 
-3.82 -10.18 0.02 0.13 0.42 2.23 0.29 4 
 
 Kianimehr et al. utilized an ANOVA, which measured the main effect of changes for 
patients on PANSS scores. They compared the score at baseline to the score after eight weeks. 
The F score was 1.77, with a p-value of 0.18. This indicates that the study does not show a 
significant difference in decrease in schizophrenia symptoms with adjunctive raloxifene 
medication.6 These results are reflected in Table 4.  
Table 4. Main effect for changes from baseline after 8 weeks of treatment6 




 Although these articles focused on the effect of raloxifene in reducing symptoms of 
schizophrenia in women by using the PANSS, some research suggests that it may be more 
effective at reducing positive symptoms than negative symptoms and general psychopathology, 
as determined by a more significant decrease in the positive subscale of the PANSS.6  
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 Raloxifene is a medication that is available worldwide, and the cost is relatively low 
compared to the economic burden of schizophrenia as a whole. The cost is around $216.21 for 30 
pills.8 The average copay for 90 tablets with most insurances is around $30.00, and it is covered 
by Medicare Part D and Medicare Advantage.9  
 In the past there have been two main uses for raloxifene. These include osteoporosis 
treatment and prevention, and reducing risk of invasive breast cancer.10 New uses for raloxifene 
also include renal and hepatic impairment in adults. raloxifene has a black box warning that it 
may increase the risk of deep vein thromboses, and pulmonary embolisms, so it is 
contraindicated in patients with a history of venous thromboembolic disorders. There is also a 
black box warning that there is an increased risk of death related to a stroke in postmenopausal 
women who have a history of coronary heart disease, and thus is contraindicated in these 
patients. Other contraindications to the use of raloxifene include pregnancy, lactation, current use 
of levothyroxine, bile acid sequestrants, or ospeifene. Patients on ralxoifene should be monitored 
with a lipid profile with women at increased risk of hypertriglyceridemia, and a Bone Mineral 
Density test one to two years after initiation of treatment, and then every one to two years after.10 
Each of the three articles found no difference in adverse effects from treatment with raloxifene 
versus the placebo, giving support that raloxifene is a safe adjunctive medication.5,6,7 
 As this study only looked at research on PubMed and Cochrane, it was limited by the 
searching methods. In addition, only looked at studies published in the past five years were 
considered, even though some research may have been conducted prior to this. Additionally, 
there were limitations in the studies themselves. All three of the studies were limited in the 
number of patients tested, with relatively low sample sizes. In addition, two of the studies lasted 
only eight6 and twelve weeks.7 Usall et al. stated that at baseline the raloxifene treatment group 
                                                                               Wilcox, Raloxifene to treat Schizophrenia 8 
had higher scores with symptoms at baseline, which allowed for more improvement in PANSS 
score compared to the control group.5 Kianimehr et al. stated that their study did not explore how 
raloxifine impacted cognition related to schizophrenia, and they simply looked at symptoms.6  
Kulkarni et al. stated that their study could be limited by the fact that there the patients were all 
on different psychiatric medications during their study.7 Overall, these studies are generalizable 
to women with schizophrenia, with limits on men and women who are pre-menopausal who have 
schizophrenia. Due to these limitations, there are still many avenues of research that need to be 
explored considering the subject of raloxifene and treatment of schizophrenia.  
CONCLUSION 
 These three randomized control trials do not give a definitive answer in whether 
raloxifene is effective as adjunctive treatment in reducing symptoms of schizophrenia in women. 
Two of the studies showed a statistically significant decrease in PANSS scores in the treatment 
group versus the control group, while the third study did not.5,6,7 One difference in the methods 
of the Kianimehr et al. study that may have altered the results is the fact that patients were not on 
treatment with antipsychotics prior to the initiation of the study. These patients began 
risperidone, an antipsychotic, only at the start of it.6 This could have contributed to their 
insignificant results in raloxifene as a method of treatment. 
 There are various improvements in study designs in the future that could better evaluate 
the efficacy of raloxifene. First, future studies should consider utilizing a larger sample 
population from more than one population, which allows for an increase in power and 
generalizability. This could include multiple hospitals, in multiple cities across the world.  In 
addition, future studies could limit extraneous variables by sampling only women who are post-
menopausal, and who are on the same antipsychotic medication prior to and during the study. A 
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third suggestion would be for studies to last at least 24 weeks with multiple measurements, much 
like the study by Usall et al.5 Finally, studies could consider comparing various doses of 
raloxifene to evaluate what dosage for women would lead to the greatest impact on the disease 
course of schizophrenia. These studies demonstrate a possible new method of treating 
schizophrenia in women who have decreased estrogen levels. More research needs to be 
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